Tabuk Pharmaceuticals

What Tabuk Pharmaceuticals does

Tabuk Pharmaceuticals is a Saudi Arabian pharmaceutical company, founded in 1994 and headquartered in Riyadh, that develops, manufactures, markets, and distributes branded generic medicines across 17 countries in the Middle East and North Africa. The company operates four state-of-the-art manufacturing sites in Tabuk and Dammam (Saudi Arabia), Sudan, and Algeria, and employs more than 2,400 professionals. Its commercial portfolio spans 17 therapeutic areas including anti-infectives (TRIAXONE, ZINOXIMOR, QUINOX, PROTEC, ZETRON, WINEX, COLAT), cardiovascular (VAROXA), gastrointestinal (TOPRAZOLE, PROKININ), dermatology, pain management, respiratory/allergy, diabetes, urology/nephrology, central nervous system, bone management, hospital products, and iron and vitamins. Tabuk is the largest privately-owned pharmaceutical company in Saudi Arabia and a fully owned subsidiary of the diversified Astra Industrial Group.

The business operates three revenue streams: (1) branded generic pharmaceuticals distributed through its own field sales and distribution network across 17 MENA countries; (2) contract manufacturing for international partners at its Saudi facilities, including technology transfer arrangements; and (3) exclusive licensing and distribution partnerships where Tabuk holds marketing authorization, handles local registration, and commercializes innovative medicines developed by global innovators. Recent high-value inbound licenses include Hanmi's Rolontis (eflapegrastim) for chemotherapy-induced neutropenia, Biocon's GLP-1 products for diabetes and weight management, Formosa's APP13007 ophthalmic suspension, Polaris's ADI-PEG20 for hard-to-treat cancers, Bio-Thera's BAT2206 (ustekinumab biosimilar), and HK inno.N's K-CAB (Tegoprazan) for GERD, with the K-CAB partnership expanded in 2025 to cover 16 MENA markets. Strategic agreements with Saudi Arabia's Local Content and Government Procurement Authority anchor Tabuk into the Kingdom's pharmaceutical localization agenda under Vision 2030, and a UAE manufacturing agreement with Globalpharma extends its production footprint beyond Saudi borders. Pricing is not publicly disclosed and the company is privately held, with no external institutional investors or public shareholders identified in the source material.

Name

Tabuk Pharmaceuticals

Legal name

Tabuk Manufacturing Company

Website

https://tabukpharmaceuticals.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Tabuk Pharmaceuticals is a Saudi Arabian, Astra Industrial Group subsidiary that develops, manufactures, and distributes branded generic and licensed specialty pharmaceutical products across 17 MENA countries from four manufacturing sites.

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Branded generic pharmaceuticals
• Pharmaceutical manufacturing services
• MENA pharmaceutical distribution
• Pharmaceutical licensing partnerships
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Branded Generic Pharmaceuticals: Develops, manufactures, markets, and distributes branded generic pharmaceutical products across 17 therapeutic categories and multiple countries in MENA region.
2. Contract Manufacturing: Manufactures pharmaceutical products for renowned international partners at its manufacturing sites in Saudi Arabia, including technology transfer arrangements.
3. Licensing and Distribution Partnerships: Acquires exclusive licensing rights for innovative medicines from international partners and commercializes them in MENA region through local registration, import, and promotion.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Tabuk Pharmaceuticals develops, manufactures, markets, and distributes branded generic pharmaceutical products across 12 therapeutic areas, operating four manufacturing sites in Saudi Arabia, Sudan, and Algeria. The company also commercializes innovative specialty medicines in the MENA region through exclusive licensing agreements with international pharmaceutical innovators, and provides contract manufacturing services to international partners. Its portfolio serves healthcare providers and patients across 17 MENA countries.

Product overview

Tabuk Pharmaceuticals is a leading Saudi pharmaceutical company that develops, manufactures, markets, and distributes branded generic medicines across 17 countries in the Middle East and North Africa (MENA) region. The company operates four state-of-the-art manufacturing sites located in Tabuk and Dammam (Saudi Arabia), Sudan, and Algeria, staffed by over 2,400 employees. Tabuk's product portfolio spans 12 therapeutic areas including Anti-infectives (TRIAXONE, ZINOXIMOR, QUINOX, PROTEC, ZETRON, WINEX, COLAT), Cardiovascular (VAROXA), Gastrointestinal (TOPRAZOLE, PROKININ), Dermatology (ZETA), Pain Management (ZENORIT), Respiratory/Allergy (TASONEX-NASAL), Iron & Vitamins (VITAGLOBIN), and more. Beyond its core branded generics business, Tabuk has established multiple strategic licensing partnerships to commercialize innovative medicines in the MENA region, including Hanmi's Rolontis (eflapegrastim) for chemotherapy-induced neutropenia, Biocon's GLP-1 products for diabetes and weight management, Formosa's APP13007 ophthalmic suspension, Polaris's ADI-PEG20 for hard-to-treat cancers, Bio-Thera Solutions' BAT2206 (ustekinumab biosimilar), and HK inno.N's K-CAB (Tegoprazan) for GERD. These partnerships leverage Tabuk's regional commercial presence and regulatory expertise while enabling access to advanced therapeutics across the MENA market.

Differentiator

Problem solved

Functional benefit

Products and services

• VAROXA Rivaroxaban-based anticoagulant indicated for venous thromboembolism (VTE), deep vein thrombosis (DVT), and stroke management, sold to healthcare providers in Saudi Arabia.
• TRIAXONE Ceftriaxone-based third-generation cephalosporin antibiotic for treatment of bacterial infections, sold to healthcare providers in Saudi Arabia.
• ZINOXIMOR Cefuroxime axetil-based cephalosporin antibiotic indicated for acute bacterial otitis media, respiratory tract infections, skin infections, urinary tract infections, gonorrhea, Lyme disease, and impetigo, sold to healthcare providers in Saudi Arabia.
• QUINOX Ciprofloxacin-based fluoroquinolone antibiotic for treatment of various bacterial infections and anthrax/plague exposure, sold to healthcare providers in Saudi Arabia.
• PROTEC Cefepime-based fourth-generation cephalosporin antibiotic for severe nosocomial pneumonia, multi-resistant infections including Pseudomonas aeruginosa, and empirical treatment of febrile neutropenia, sold to hospital accounts in Saudi Arabia.
• TOPRAZOLE Pantoprazole-based proton pump inhibitor for treatment of erosive esophagitis, GERD, and Zollinger-Ellison syndrome, sold to healthcare providers in Iraq.
• ZENORIT
• TASONEX-NASAL Mometasone furoate corticosteroid nasal spray for treatment of allergic rhinitis, nasal congestion, and nasal polyps, sold to healthcare providers in Algeria.
• VITAGLOBIN Multivitamin and mineral supplement sold to healthcare providers and pharmacies in Algeria.
• Rolontis (Eflapegrastim) Innovative biologic developed by Hanmi Pharmaceutical for treatment of chemotherapy-induced neutropenia, licensed exclusively to Tabuk for Saudi Arabia and MENA region commercialization.
• K-CAB (Tegoprazan) Novel potassium-competitive acid blocker (P-CAB) developed by HK inno.N for treatment of gastroesophageal reflux disease (GERD) and acid-related conditions, licensed exclusively to Tabuk for MENA region commercialization.
• Biocon GLP-1 Products Glucagon-like peptide-1 medications for diabetes and chronic weight management, developed and manufactured by Biocon Limited, with Tabuk holding marketing authorization rights for the Middle East region.
• APP13007 (Clobetasol Propionate Ophthalmic Suspension 0.05%) Patented innovative ophthalmic suspension using Formosa Pharmaceuticals' APPNTTM nanoparticle formulation platform for treatment of inflammation and pain following ocular surgery, licensed exclusively to Tabuk for MENA region commercialization.
• ADI-PEG20 (ADZODI) First-in-class arginine degradation platform biologic for treatment of Malignant Pleural Mesothelioma and other hard-to-treat cancers, developed by Polaris Pharmaceuticals and licensed exclusively to Tabuk for Saudi Arabia and GCC commercialization.
• BAT2206 (Ustekinumab Biosimilar) Proposed biosimilar to Janssen's Stelara (ustekinumab), a human monoclonal antibody inhibiting IL-12 and IL-23 for autoimmune diseases, manufactured by Bio-Thera Solutions and licensed exclusively to Tabuk for Saudi Arabia.
• Contract Manufacturing Services Contract manufacturing services where Tabuk produces pharmaceutical products on behalf of international partners at its four state-of-the-art manufacturing sites in Saudi Arabia, Sudan, and Algeria, with technology transfer capabilities.

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core.

• Althera LaboratoriescoreStrategic or Co-development Partner · 28 October 2025Strategic partnership to develop and commercialize an advanced Type 2 Diabetes therapy in MENA region. Regulatory submission expected in spring 2026. Leverages Althera's expertise in combination therapies and Tabuk's regional commercial presence across 17 countries.
• Local Content and Government Procurement AuthoritycoreStrategic or Co-development Partner · 1 October 2025Two strategic agreements signed at Global Health Exhibition 2025 for pharmaceutical localization and advancing Kingdom's healthcare capabilities. Supports Saudi Vision 2030 and national health security.
• Hanmi PharmaceuticalcoreOEM/ Whitelabel/ Licensing Partner · 8 September 2025Exclusive license and supply agreement for Rolontis (Eflapegrastim), an innovative biologic for chemotherapy-induced neutropenia, across Saudi Arabia and MENA. Alignment with Saudi Vision 2030 for access to advanced biologics.
• Polaris PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 10 June 2025Exclusive licensing agreement for ADI-PEG20 (ADZODI), a first-in-class arginine degradation platform for hard-to-treat cancers including Malignant Pleural Mesothelioma, in Saudi Arabia and GCC region.
• HK inno.NcoreOEM/ Whitelabel/ Licensing Partner · 7 May 2025Expanded strategic collaboration for K-CAB (Tegoprazan), an innovative GERD treatment. Original agreement covered 10 MENA countries; expansion adds 6 countries: Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya.
• Biocon LimitedcoreOEM/ Whitelabel/ Licensing Partner · 5 May 2025Licensing and supply agreement to commercialize GLP-1 products for diabetes and chronic weight management in Middle East. Includes technology transfer option for localized manufacturing.
• Formosa PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 4 May 2025Exclusive license agreement for commercialization of clobetasol propionate ophthalmic suspension 0.05% (APP13007), a patented innovative medicine for treatment of inflammation and pain following ocular surgery in MENA.
• GlobalpharmacoreStrategic or Co-development Partner · 3 May 2025Cooperation agreement for local manufacturing of several products including cardiovascular medicines and analgesics (NSAIDs) in UAE. Signed at Arab Health 2024 Exhibition. Supports 'Make it in the Emirates' initiative.
• Bio-Thera SolutionscoreOEM/ Whitelabel/ Licensing Partner · 17 December 2024License, manufacturing, supply and commercialization agreement for BAT2206, a ustekinumab biosimilar (Stelara). Tabuk holds exclusive rights in Saudi Arabia for marketing authorization, manufacture, import, and promotion.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-based pharmaceutical manufacturer with multi-therapeutic-area branded generics portfolio across MENA. SPIMACO is the closest domestic peer to Tabuk, competing in the same Saudi market and similar regional therapeutic categories.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generics and specialty pharmaceutical company with deep MENA manufacturing and distribution presence. Hikma's branded generics plus injectable specialty franchise and MENA commercial footprint closely mirror Tabuk's strategic positioning.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing branded generics across MENA with multiple manufacturing sites. Julphar competes directly with Tabuk in MENA markets across similar therapeutic categories and shares the regional branded-generics business model.
• Eva Pharma: Egypt-based pharmaceutical company producing branded generics across therapeutic categories with growing MENA regional presence. Eva Pharma is a comparable regional generic manufacturer with similar therapeutic breadth and emerging export footprint.

Regional players

• Pharma International Company: Jordan-based pharmaceutical manufacturer with branded generics portfolio across MENA. Pharma International competes with Tabuk in regional markets but is primarily Jordan-anchored rather than Saudi-headquartered.
• Aspen Pharmacare: South Africa-headquartered specialty and generics pharmaceutical company with presence in emerging markets including MENA. Aspen's branded generics plus specialty licensing model across emerging markets is structurally comparable to Tabuk's, though it operates in different geographies.

Broad incumbents

• Dr. Reddy's Laboratories: India-based global generics and specialty pharmaceutical major with established MENA commercial presence. Dr. Reddy's competes with Tabuk in selected MENA product categories and represents a global generics benchmark.
• Cipla: India-based global pharmaceutical company with significant branded generics presence across MENA markets. Cipla competes with Tabuk in respiratory, anti-infectives, and other core therapeutic categories in regional markets.
• Aurobindo Pharma: India-based global generics manufacturer with API and finished-dose capabilities and growing emerging-markets presence. Aurobindo is a comparable scale global generics player that intersects with Tabuk in selected MENA product categories.
• Sanofi: Global pharmaceutical major with significant MENA commercial and manufacturing operations, including branded specialty products. Sanofi is a relevant broad incumbent competing with Tabuk in cardiovascular, diabetes, and specialty categories across MENA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/TabukPharma
• Facebookfacebook.com/TabukPharmaceutical
• LinkedInlinkedin.com/company/tabuk-pharmaceutical-mfg-co

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tabuk Pharmaceuticals